How can the low antibody immobilization efficiency on an immunocapture microfluidic chip be optimized?

When looking for suppliers, prioritize those with ISO13485 certification or mass production experience in CTC/immunodiagnostic consumables. Pure research-oriented processing factories may not understand how to preserve antibody activity. You can ask whether they offer different pre-modification options such as amination, streptavidin, or aldehyde functionalization, and whether they can do small-batch validation with 3-5 chip samples. Require batch-to-batch binding capacity data, preferably tested with biotinylated fluorescent probes. Also ask about storage and stability, as many pre-modified surfaces lose activity over time and require vacuum or refrigerated packaging. There are optional plastic chip solutions within 100 yuan, but if glass bonding and fully automated coating are added, that may not be enough. First obtain samples and run CTC spike-in recovery tests in your own system, and only discuss bulk orders after meeting the required performance.

COC is relatively hydrophobic, and direct physical adsorption of EpCAM antibodies tends to cause denaturation, poor orientation, and low activity, which is not surprising. It is recommended to switch to covalent conjugation: first activate the surface with UV/ozone or plasma to introduce carboxyl/hydroxyl groups, then activate with EDC/NHS before conjugating the antibody; alternatively, use biotinylated antibodies with streptavidin pre-modification, which will improve orientation and activity. For the amination or streptavidin pre-modification you mentioned, domestic manufacturers specializing in IVD chip surface modification can provide these. You should ask them for surface amine density, streptavidin binding capacity, and uniformity data, and not just look at the words "pre-modified." A budget of around 100 per slide is feasible for mass production, but only if you scale up.

For 2 mL of whole blood, 5 μL/min is not a short duration, and if whole blood is loaded directly onto the chip, red blood cells and white blood cells will nonspecifically occupy the surface and may also cause clogging. It is recommended to first remove red blood cells using red blood cell lysis buffer or density gradient centrifugation, then dilute with BSA-containing buffer. Blocking is very important: after antibody immobilization, block with 1%-5% BSA or casein for 1 h to reduce nonspecific adsorption. To verify immobilization efficiency, use fluorescently labeled secondary antibodies or directly labeled EpCAM antibodies to measure fluorescence intensity within the chip, then spike samples with a known number of tumor cells to assess recovery. It would be better if the modification vendor could provide a pre-blocking or lyophilization protection solution. Before changing suppliers, first standardize your own pretreatment and blocking protocol; otherwise, it is easy to misjudge the issue as a chip problem.